NCT01627678View on ClinicalTrials.gov

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
HIV-1 Infection
Interventions
DRUG

Vacc-C5/GM-CSF

Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.

DRUG

Vacc-C5/Alhydrogel

Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.

Trial Locations (1)

0450

Oslo University Hospital, Ullevål, Oslo

All Listed Sponsors
lead

Bionor Immuno AS

INDUSTRY

NCT01627678 - Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART | Biotech Hunter | Biotech Hunter